Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30 June 2024.
Highlights from the period include:
- GMP production run of PAT-DX1 completed during the quarter with specification testing scheduled to be completed by end of July 2024;
- Positive preclinical data demonstrating potential to use deoxymabs to treat vasculitis, and potentially other autoimmune diseases, presented at international meetings;
- Cash and short‑term investment balance of $2.2 million on 30 June 2024.
Patrys CEO and MD, Dr James Campbell said:
“The focus for Patrys for the April-June period was the GMP manufacturing run of PAT-DX1 which was completed during the quarter. Our Contract Manufacturing and Development Organisation advised that specification testing of the drug material from this production run is scheduled to be completed by the end of July — approximately one month later than the Company was expecting. This specification testing must be successfully completed before the drug material can be released for use in clinical trials. We were also pleased to receive positive data from preclinical studies that further highlight the potential to use our deoxymabs for various autoimmune diseases.”